Neurocrine Biosciences names new director
12 September 2019 -

Neurocrine Biosciences Inc (NASDAQ: NBIX), a neuroscience-focused, biopharmaceutical company, announced yesterday that it has named Leslie V Norwalk as its new director.

Norwalk formerly served as Acting Administrator for the Centers for Medicare & Medicaid Services and is presently Strategic Counsel to healthcare companies at Epstein Becker Green, EBG Advisors and National Health Advisors. She serves as a director of NuVasive, Endologix, Providence Service Corporation, Magellan Health, and Arvinas, and several privately-held healthcare companies. She also serves as a healthcare, regulatory and policy advisor to several private equity firms.

William H Rastetter, Chairman of the Board of Neurocrine Biosciences, said, 'We are excited to welcome Leslie Norwalk to the Neurocrine Biosciences Board of Directors. Leslie's tenure as an administrator at the Centers for Medicare & Medicaid Services, coupled with her extensive background in healthcare policy and regulatory matters will be invaluable as Neurocrine Biosciences continues to grow and evolve as a commercial-stage biopharmaceutical company focused on developing life-changing treatments for people with neurological, endocrine and psychiatric disorders.'